Novartis bets $1.6B on a biotech’s anti-inflammatory drugs
Novartis could spend almost $1.6B on a collection of experimental anti-inflammatory drugs from a subsidiary of IFM Therapeutics. IFM has approved the transaction, which they expect to close in the second quarter.
The pipeline includes three drugs that inhibit a protein involved in immune system regulation. One of them, IFM-2427, just entered a Phase 1 study, while the other two are still in preclinical testing.
